ACTRN12606000533594已完成3 期
Adjuvant tamoxifen longer against shorter (ATLAS) clinical trial in early breast cancer. Reliable assessment of the efficacy and safety of prolonging the use of adjuvant tamoxifen: a large, simple, randomised study.
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 20,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- Female
入选标准
- •Women who have received any type of curative surgery for early breast cancer are eligible (irrespective of the original histological type of the disease, nodal status, or whether the tumour was estrogen receptor positive or negative) so long as the woman appears currently to be free of breast cancer and is receiving tamoxifen and where both the woman and her doctor are uncertain whether to continue with tamoxifen.
排除标准
- •No exclusion criteria
研究者
相似试验
已完成
不适用
Adjuvant Tamoxifen Treatment - offer more? To assess reliably the balance of benefits and risks of prolonging adjuvant tamoxifen treatment by 5 years for women with breast cancerCancerBreast cancerISRCTN17222211The University of Birmingham (UK)6,953
进行中（未招募）
不适用
etrozole adjuvant therapy after tamoxifen. Study of gene CYP19 correlation with letrozole efficacy in postmenopausal early breast cancer patientsPatients selection to give letrozole for 5 years after 5 years of tamoxifen as adjuvant hormonal therapyMedDRA version: 14.1Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-001213-18-ITCONSORZIO ONCOTECH
招募中
不适用
Tamoxifen preventive studyBreast cancerJPRN-jRCTs031200222akamura Seigo210
已完成
3 期
ALTTO(Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) trialHER2/ErbB2 positive primary breast cancerJPRN-jRCT2080220464ovartis Pharma K.K8,000
已完成
3 期
Phase III Randomized Adjuvant Study of Tamoxifen Alone Versus Sequential Tamoxifen and Anastrozole in Hormone-Responsive Postmenopausal Breast Cancer PatientsHormone-responsive postmenopausal primary breast cancerJPRN-C000000056-SAS BC 03 executive committee2,500